· Trials · Trials Desk
Short-term weight loss favored the procedural arm, complicating the narrative that GLP-1 drugs will fully displace bariatric and endoscopic interventions.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.